Does the media favor ONC or CRNX?

In the previous week, BeOne Medicines had 20 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 31 mentions for BeOne Medicines and 11 mentions for Crinetics Pharmaceuticals. BeOne Medicines' average media sentiment score of 0.58 beat Crinetics Pharmaceuticals' score of 0.42 indicating that BeOne Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 9 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor RPRX or CRNX?

In the previous week, Royalty Pharma had 12 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 23 mentions for Royalty Pharma and 11 mentions for Crinetics Pharmaceuticals. Royalty Pharma's average media sentiment score of 1.02 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 11 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CRNX or ZTS?

In the previous week, Zoetis had 32 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 43 mentions for Zoetis and 11 mentions for Crinetics Pharmaceuticals. Zoetis' average media sentiment score of 0.52 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Zoetis 17 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor VTRS or CRNX?

In the previous week, Viatris had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 14 mentions for Viatris and 11 mentions for Crinetics Pharmaceuticals. Viatris' average media sentiment score of 0.52 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor NBIX or CRNX?

In the previous week, Neurocrine Biosciences had 24 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 35 mentions for Neurocrine Biosciences and 11 mentions for Crinetics Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.77 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 15 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Crinetics Pharmaceuticals (CRNX) Competitors

$84.08 +0.16 (+0.19%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$84.17 +0.09 (+0.10%)

As of 08/7/2026 07:57 PM Eastern

Compare

CRNX vs. ONC, RPRX, ZTS, VTRS, and NBIX

Should you buy Crinetics Pharmaceuticals stock or one of its competitors? MarketBeat compares Crinetics Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Crinetics Pharmaceuticals include BeOne Medicines (ONC), Royalty Pharma (RPRX), Zoetis (ZTS), Viatris (VTRS), and Neurocrine Biosciences (NBIX). These companies are all part of the "pharmaceuticals" industry.

How does Crinetics Pharmaceuticals compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

BeOne Medicines has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$6.13B	6.23	$286.93M	$5.68	61.32
Crinetics Pharmaceuticals	$42.16M	211.55	-$465.32M	-$5.04	N/A

BeOne Medicines has a net margin of 10.70% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. BeOne Medicines' return on equity of 14.23% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	10.70%	14.23%	7.82%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, BeOne Medicines had 20 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 31 mentions for BeOne Medicines and 11 mentions for Crinetics Pharmaceuticals. BeOne Medicines' average media sentiment score of 0.58 beat Crinetics Pharmaceuticals' score of 0.42 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	9 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

BeOne Medicines currently has a consensus price target of $400.00, suggesting a potential upside of 14.85%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 3.66%. Given BeOne Medicines' stronger consensus rating and higher probable upside, equities analysts plainly believe BeOne Medicines is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Summary

BeOne Medicines beats Crinetics Pharmaceuticals on 15 of the 17 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Royalty Pharma has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.54B	12.89	$770.95M	$1.45	39.15
Crinetics Pharmaceuticals	$42.16M	211.55	-$465.32M	-$5.04	N/A

Royalty Pharma has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market.

Royalty Pharma currently has a consensus target price of $60.86, suggesting a potential upside of 7.20%. Crinetics Pharmaceuticals has a consensus target price of $81.00, suggesting a potential downside of 3.66%. Given Royalty Pharma's stronger consensus rating and higher probable upside, equities analysts plainly believe Royalty Pharma is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Royalty Pharma has a net margin of 32.14% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Royalty Pharma's return on equity of 30.01% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

In the previous week, Royalty Pharma had 12 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 23 mentions for Royalty Pharma and 11 mentions for Crinetics Pharmaceuticals. Royalty Pharma's average media sentiment score of 1.02 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	11 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Royalty Pharma beats Crinetics Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Zoetis?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Zoetis (NYSE:ZTS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

Zoetis has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$42.16M	211.55	-$465.32M	-$5.04	N/A
Zoetis	$9.53B	3.19	$2.67B	$6.07	11.95

Crinetics Pharmaceuticals has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

Zoetis has a net margin of 27.49% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Zoetis' return on equity of 70.95% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Zoetis	27.49%	70.95%	18.54%

Crinetics Pharmaceuticals currently has a consensus price target of $81.00, indicating a potential downside of 3.66%. Zoetis has a consensus price target of $115.50, indicating a potential upside of 59.25%. Given Zoetis' stronger consensus rating and higher possible upside, analysts plainly believe Zoetis is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Zoetis	1 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.35

In the previous week, Zoetis had 32 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 43 mentions for Zoetis and 11 mentions for Crinetics Pharmaceuticals. Zoetis' average media sentiment score of 0.52 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Zoetis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Zoetis	17 Very Positive mention(s)	4 Positive mention(s)	12 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 92.8% of Zoetis shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Zoetis beats Crinetics Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

79.9% of Viatris shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Viatris currently has a consensus price target of $17.50, suggesting a potential upside of 6.51%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 3.66%. Given Viatris' stronger consensus rating and higher probable upside, analysts clearly believe Viatris is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Viatris has a net margin of -2.79% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Viatris' return on equity of 20.02% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

In the previous week, Viatris had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 14 mentions for Viatris and 11 mentions for Crinetics Pharmaceuticals. Viatris' average media sentiment score of 0.52 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Crinetics Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.74B	1.30	-$3.51B	-$0.36	N/A
Crinetics Pharmaceuticals	$42.16M	211.55	-$465.32M	-$5.04	N/A

Summary

Viatris beats Crinetics Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Crinetics Pharmaceuticals compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Neurocrine Biosciences has a net margin of 20.91% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Neurocrine Biosciences' return on equity of 22.43% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Neurocrine Biosciences has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market.

In the previous week, Neurocrine Biosciences had 24 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 35 mentions for Neurocrine Biosciences and 11 mentions for Crinetics Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.77 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	15 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Neurocrine Biosciences presently has a consensus target price of $201.50, suggesting a potential upside of 23.31%. Crinetics Pharmaceuticals has a consensus target price of $81.00, suggesting a potential downside of 3.66%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Neurocrine Biosciences has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.81	$478.60M	$6.82	23.96
Crinetics Pharmaceuticals	$42.16M	211.55	-$465.32M	-$5.04	N/A

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Neurocrine Biosciences beats Crinetics Pharmaceuticals on 15 of the 17 factors compared between the two stocks.

Get Crinetics Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRNX vs. The Competition

Export

Metric	Crinetics Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.92B	$11.85B	$7.01B	$13.00B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	-16.68	790.97	271.11	25.19
Price / Sales	211.55	743.77	596.29	80.06
Price / Cash	N/A	71.16	71.81	50.72
Price / Book	7.48	10.75	13.25	6.22
Net Income	-$465.32M	$2.78B	$3.45B	$342.66M
7 Day Performance	0.67%	3.36%	4.67%	4.41%
1 Month Performance	0.55%	-0.81%	-1.28%	-1.10%
1 Year Performance	213.15%	192.86%	77.33%	23.99%

Crinetics Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRNX Crinetics Pharmaceuticals	1.8218 of 5 stars	$84.08 +0.2%	$81.00 -3.7%	+213.1%	$8.92B	$42.16M	N/A	210	News Coverage Earnings Report
ONC BeOne Medicines	4.091 of 5 stars	$313.77 -0.7%	$394.00 +25.6%	+20.9%	$34.67B	$5.34B	70.19	12,000	Trending News Earnings Report Analyst Forecast Insider Trade
RPRX Royalty Pharma	4.5537 of 5 stars	$57.17 -2.2%	$56.57 -1.0%	+51.1%	$33.65B	$2.38B	38.89	80	Positive News Earnings Report Analyst Forecast
ZTS Zoetis	4.9836 of 5 stars	$77.13 -0.2%	$118.33 +53.4%	-50.8%	$32.40B	$9.47B	12.79	14,500	Trending News Earnings Report Analyst Forecast
VTRS Viatris	2.3843 of 5 stars	$17.63 +0.4%	$17.50 -0.7%	+69.4%	$20.45B	$14.30B	N/A	30,000	Trending News Earnings Report Dividend Announcement Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRNX) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crinetics Pharmaceuticals (CRNX) Competitors

CRNX vs. ONC, RPRX, ZTS, VTRS, and NBIX

How does Crinetics Pharmaceuticals compare to BeOne Medicines?

Summary

How does Crinetics Pharmaceuticals compare to Royalty Pharma?

Summary

How does Crinetics Pharmaceuticals compare to Zoetis?

Summary

How does Crinetics Pharmaceuticals compare to Viatris?

Summary

How does Crinetics Pharmaceuticals compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX vs. The Competition

Crinetics Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crinetics Pharmaceuticals (CRNX) Competitors

CRNX vs. ONC, RPRX, ZTS, VTRS, and NBIX

How does Crinetics Pharmaceuticals compare to BeOne Medicines?

Which has more risk & volatility, ONC or CRNX?

Which has higher valuation & earnings, ONC or CRNX?

Is ONC or CRNX more profitable?

Do insiders and institutionals hold more shares of ONC or CRNX?

Does the media favor ONC or CRNX?

Do analysts rate ONC or CRNX?

Summary

How does Crinetics Pharmaceuticals compare to Royalty Pharma?

Which has higher earnings & valuation, RPRX or CRNX?

Which has more volatility and risk, RPRX or CRNX?

Do analysts prefer RPRX or CRNX?

Is RPRX or CRNX more profitable?

Does the media favor RPRX or CRNX?

Do institutionals & insiders hold more shares of RPRX or CRNX?

Summary

How does Crinetics Pharmaceuticals compare to Zoetis?

Which has better earnings & valuation, CRNX or ZTS?

Which has more volatility & risk, CRNX or ZTS?

Is CRNX or ZTS more profitable?

Do analysts prefer CRNX or ZTS?

Does the media refer more to CRNX or ZTS?

Do institutionals and insiders have more ownership in CRNX or ZTS?

Summary

How does Crinetics Pharmaceuticals compare to Viatris?

Do insiders & institutionals hold more shares of VTRS or CRNX?

Do analysts rate VTRS or CRNX?

Which has more volatility and risk, VTRS or CRNX?

Is VTRS or CRNX more profitable?

Does the media favor VTRS or CRNX?

Which has better valuation and earnings, VTRS or CRNX?

Summary

How does Crinetics Pharmaceuticals compare to Neurocrine Biosciences?

Is NBIX or CRNX more profitable?

Which has more volatility & risk, NBIX or CRNX?

Does the media favor NBIX or CRNX?

Do analysts rate NBIX or CRNX?

Which has higher earnings & valuation, NBIX or CRNX?

Do insiders and institutionals hold more shares of NBIX or CRNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRNX vs. The Competition

Crinetics Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools